Deargen

Deargen is a South Korean biotechnology company specializing in artificial intelligence-driven drug discovery and development. The company utilizes its proprietary deep learning platform, Dr.Dearman, to predict drug-target interactions and accelerate the identification of novel therapeutic candidates. By integrating genomic data with chemical structures, Deargen streamlines the hit-to-lead process and optimizes drug properties for various indications, including oncology and metabolic diseases. The company gained international recognition for its early AI-based prediction of Remdesivir's efficacy against COVID-19. Deargen operates through a hybrid business model, pursuing both internal drug development and strategic collaborations with global pharmaceutical partners.